Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

doi:10.1200/JCO.2015.63.1010

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2017

Symmans W Fraser, Wei Caimiao, Gould Rebekah, Yu Xian, Zhang Ya, Liu Mei, Walls Andrew, Bousamra Alex, Ramineni Maheshwari, Sinn Bruno, Hunt Kelly, Buchholz Thomas A, Valero Vicente, Buzdar Aman U, Yang Wei, Brewster Abenaa M, Moulder Stacy, Pusztai Lajos, Hatzis Christos, Hortobagyi Gabriel N

Abstract excerpt

Purpose To determine the long-term prognosis in each phenotypic subset of breast cancer related to residual cancer burden (RCB) after neoadjuvant chemotherapy alone, or with concurrent human epidermal growth factor receptor 2 (HER2)-targeted treatment. Methods We conducted a pathologic review to measure the continuous RCB index (wherein pathologic complete response has RCB = 0; residual disease is categorized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Doxorubicin

Share to Epirubicin

Share to Neoadjuvant Therapy

Share to Neoplasm, Residual

Share to Paclitaxel

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 28135148
DOI: 10.1200/JCO.2015.63.1010
PMCID: PMC5455352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.PMID 28135148Read ↗

Preoperative Prediction of Residual Cancer Burden After Neoadjuvant Chemotherapy in Breast Cancer: A Multimodal Machine Learning Approach and Implications for Clinical Decision SupportSemantic proximity Read ↗

Clinical Validation of RlapsRisk BC in an international multi-cohorts settingSemantic proximity Read ↗

Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast CancerSemantic proximity Read ↗

Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive reviewSemantic proximity Read ↗

Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer.Semantic proximity Read ↗

Comparison of time-varying recurrence patterns in breast cancer patients with different molecular subtypes treated from 2008 to 2012 and from 2013 to 2016: a single-center retrospective studySemantic proximity Read ↗

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read ↗

Development of a Prognostic Model for HR-positive HER2-negative and Node-negative Breast Cancer: Integrating Clinical and Transcriptional BiomarkersSemantic proximity Read ↗

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceSemantic proximity Read ↗

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity Read ↗

Multimodal histopathologic models stratify hormone receptor-positive early breast cancerSemantic proximity Read ↗

Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.